Disclosures: Fatima DAHBOUL: Nothing to Disclose, JIHAN SUN: Nothing to Disclose, Benjamin Buchard: Nothing to Disclose, Delphine Weil-Verhoeven: Nothing to Disclose, Vincent Di Martino: Nothing to Disclose, Aicha Demidem: Nothing to Disclose, Armand Abergel: Nothing to Disclose 1875 RADIOMICS-BASED PREDICTION OF HCC RESPONSE TO ATEZOLIZUMAB/BEVACIZUMAB Isaac Israel Rodriguez Salazar 1 Andreas Teufel 1 Abhinay Vellala 1 Timo Itzel 1 Jimmy Daza 1 Michael Vcha 1 Manuel Debic 2 De-Hua Chang 3 Michael Dill 2 Max Seidensticker 4 Gerd Oswald Stefan Schnberg 1 Lukas Mller 5 Julia Mayerle 4 Stefan Munker 4 Peter Galle 5 Arndt Weinmann 5 Dietmar Tamandl 6 Matthias Pinter 6 Marino Venerito 7 Matthias Ebert 1 Matthias Froelich 1 Maciej Pech 7 Friedrich Sinner 7 Bernhard Scheiner 6 , 1 Medical Faculty Mannheim, 2 Medical Faculty Heidelberg, 3 Cantonal Hospital of Lucerne, 4 LMU Munich, 5 University Medical Center Mainz, 6 Medical Faculty Vienna, 7 Magdeburg University Background: Atezolizumab/ bevacizumab has emerged as a breakthrough therapy for advanced hepatocellular carcinoma (HCC)
doi: 10.1016/j.ecoenv.2024.116064 169 LiuJ.TanY.ChengH.ZhangD.FengW.PengC
HOW WE HELP Accurate Diagnosis Our providers order and review targeted lab work, ferritin, hemoglobin, and iron studies, to accurately confirm iron deficiency or anemia before recommending infusion therapy, ensuring the right treatment for your specific labs
J., Leow, A
